Suppr超能文献

病毒样疫苗对抗 HIV/SIV 与亚优势抗原 T 细胞疫苗具有协同作用。

Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.

机构信息

Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Mærsk Tower 07-11, Blegdamsvej 3B, 2200, Copenhagen N, Denmark.

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via L. Armanni 5, 80138, Naples, Italy.

出版信息

J Transl Med. 2019 May 24;17(1):175. doi: 10.1186/s12967-019-1924-1.

Abstract

BACKGROUND

In non-human primates (NHPs) and humans, partial protection from HIV/SIV infection or suppression of replication is achievable by Env-binding antibodies and Gag-specific CD8+ T-cells targeting protective epitopes. Unfortunately, such T-cell responses are frequently dominated by responses to non-protective, variable epitopes. In this study we attempt to combine three independent approaches, each developed to prevent immunodominance of non-protective epitopes. These approaches were (1) vaccines consisting exclusively of putatively protective p24 Gag highly conserved elements (CEs), (2) vaccines using solely subdominant antigens which were acutely protective in a recent NHP trial, and (3) virus-encoded virus-like particle vaccines (virus-like vaccines/VLVs) using heterologous Env and Gag sequences to enable selection of broadly cross-reactive responses and to avoid immunodominance of non-conserved sequences in prime-boost regimens as previously observed.

METHODS

We vaccinated outbred CD1 mice with HIV-1 clade B Gag/Env encoded in an adenoviral prime and SIVmac239 Gag/Env in an MVA boost. We combined this completely heterologous immunization regimen and the homologous SIVmac239 Gag/Env immunization regimen with an additional prime encoding SIV CEs and accessory antigens Rev, Vif and Vpr (Ad-Ii-SIVCErvv). T-cell responses were analyzed by intracellular cytokine staining of splenocytes and antibody responses by trimer-specific ELISA, avidity and isotype-specific ELISA.

RESULTS

Env dominance could be avoided successfully in the completely heterologous prime-boost regimen, but Env immunodominance reappeared when Ad-Ii-SIVCErvv was added to the prime. This regimen did however still induce more cross-reactive Gag-specific CD8+ T-cells and Env-specific antibodies. Including Ad-Ii-SIVCErvv in the homologous prime-boost not only elicited accessory antigen-specific CD8+ memory T-cells, but also significantly increased the ratio of Gag- to Env-specific CD8+ T-cells. The CD4+ T-cell response shifted away from structural antigens previously associated with infection-enhancement.

CONCLUSION

The homologous Gag/Env prime-boost with Ad-Ii-SIVCErvv prime combined acutely protective CD8+ T-cell responses to subdominant antigens and Env-binding antibodies with chronically protective Gag-specific CD8+ T-cells in outbred mice. This vaccine regimen should be tested in an NHP efficacy trial.

摘要

背景

在非人类灵长类动物(NHPs)和人类中,Env 结合抗体和针对保护性表位的 Gag 特异性 CD8+T 细胞可实现部分预防 HIV/SIV 感染或抑制复制。不幸的是,这种 T 细胞反应通常受针对非保护性、可变表位的反应所主导。在这项研究中,我们试图结合三种独立的方法,每种方法都旨在防止非保护性表位的免疫优势。这些方法是:(1)仅由推定保护性 p24 Gag 高度保守元件(CEs)组成的疫苗;(2)使用最近在 NHP 试验中具有急性保护作用的仅亚优势抗原的疫苗;和(3)使用异源 Env 和 Gag 序列的病毒编码病毒样颗粒疫苗(病毒样疫苗/VLVs),以能够选择广泛交叉反应性的反应,并避免在初次-加强方案中观察到的非保守序列的免疫优势,如前所述。

方法

我们用编码 HIV-1 克拉德 B Gag/Env 的腺病毒进行初次免疫,用 SIVmac239 Gag/Env 在 MVA 加强免疫,对 CD1 近交系小鼠进行疫苗接种。我们将这种完全异源免疫方案与同源 SIVmac239 Gag/Env 免疫方案相结合,并在初次免疫中添加编码 SIV CEs 和辅助抗原 Rev、Vif 和 Vpr 的基因(Ad-Ii-SIVCErvv)。通过脾细胞内细胞因子染色分析 T 细胞反应,通过三聚体特异性 ELISA、亲和力和同种型特异性 ELISA 分析抗体反应。

结果

在完全异源的初次-加强方案中可以成功避免Env 优势,但当 Ad-Ii-SIVCErvv 添加到初次免疫中时,Env 免疫优势再次出现。然而,该方案仍然诱导了更多的交叉反应性 Gag 特异性 CD8+T 细胞和 Env 特异性抗体。在同源初次-加强方案中包含 Ad-Ii-SIVCErvv 不仅诱导了辅助抗原特异性 CD8+记忆 T 细胞,而且还显著增加了 Gag 特异性 CD8+T 细胞与 Env 特异性 CD8+T 细胞的比例。CD4+T 细胞反应从先前与感染增强相关的结构抗原转移。

结论

在近交系小鼠中,用 Ad-Ii-SIVCErvv 进行同源 Gag/Env 初次-加强方案相结合,可产生针对亚优势抗原的急性保护性 CD8+T 细胞反应,并产生针对 Gag 的慢性保护性 CD8+T 细胞反应特异性抗体。这种疫苗方案应在 NHP 功效试验中进行测试。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7fd/6534914/1a2fbf276b43/12967_2019_1924_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验